Compare BLBD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | ORKA |
|---|---|---|
| Founded | 1927 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2013 | N/A |
| Metric | BLBD | ORKA |
|---|---|---|
| Price | $58.71 | $53.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $67.17 | $57.25 |
| AVG Volume (30 Days) | 294.0K | ★ 743.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $1,480,099,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $62.38 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.32 | $5.49 |
| 52 Week High | $62.90 | $53.56 |
| Indicator | BLBD | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 77.60 |
| Support Level | $53.24 | $26.02 |
| Resistance Level | $59.42 | N/A |
| Average True Range (ATR) | 1.93 | 2.98 |
| MACD | 0.38 | 1.17 |
| Stochastic Oscillator | 88.13 | 98.44 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.